Phase 3 Study of MAP0004 in Adult Migraineurs

Study Identifier
MAP0004 CL P301
CT.gov Identifier
NCT00623636
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Migraine - General
    • Study Drug
  • MAP0004
  • Placebo
    • Phase
    Phase 3
    Sex
    Female & Male
    Age
    18 - 65 Years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    Major Inclusion Criteria: * Male or female between 18 and 65 years of age. * History of episodic, acute migraine (with or without aura) with onset prior to 50 Major Exclusion Criteria: * Known allergy or sensitivity or contraindication to study drugs or their formulations * History of chronic pulmonary disease, coronary artery disease (CAD), liver disease, kidney disease, seizures, stroke, or major psychiatric condition. * Any condition that, in the opinion of the Investigator, would make the subject unsuitable for study participation

    Protocol Summary

    This is a randomized, double blind, placebo controlled, parallel group study of MAP0004 in adult migraineurs. Subjects will self administer study drug in the outpatient setting.

    Study Locations

    Location
    Status
    Location
    Swedish Pain and Headache Clinic
    Seattle, Washington, United States, 98104
    Status
    Not applicable